DanCann Pharma A/S Successfully Receives First Tranche from the 10-Year Financing Loan-Agreement with 12-months Conversion Option and Warrants with Nordic Growth Opportunities 2
COPENHAGEN, Denmark, 17 July 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce, that the Company based on an authorization from the general meeting, resolved to issue loan notes to an aggregate amount of DKK 18,900,000, and 8,190,000 warrants to Nordic Growth Opportunities 2 (the “Investor” or “NGO2”) in connection with the Company’s receipt of first tranche of DKK 6,600,000 of the total loan from the Investor pursuant to the financing agreement entered into with the Investor as described in a